In vitro Open Complex formation and full-length transcription assays
Open complex formation assays were performed in a 10 µl volume containing: 10 mM Tris-acetate (pH 8.0), 50 mM potassium acetate, 8 mM magnesium acetate, 0.1 mM DTT, 4 mM dATP, 0.1 µM core RNAP enzyme, 0.4 µM σ 54 and 20 nM promoter DNA (supercoiled S. meliloti nifH promoter). The mix was pre-incubated at 37°C for 5 minutes and the reaction started by addition of 5 µM of PspF 1-275 WT or variants and incubated for varying times at 37°C. Open complex formation was monitored following the synthesis of the transcript (-1 UpGGG+3) started by simultaneous addition of heparin (100 µg/ml), initiating dinucleotide UpG (0.5 mM), GTP (0.01 mM) and 4 µCi [α-32 P]GTP for a further 10 minutes. The reaction was stopped by addition of loading buffer and analyzed on a 20% denaturating gel. Full-length transcription was initiated by adding a mix containing 100 μg/ml heparin, 1 mM ATP, CTP, GTP, 0.5 mM UTP and 3 μCi [α-
32
P]UTP for a further 10 minutes. The reaction was stopped by addition of loading buffer and analyzed on 6% sequencing gels.
Radiolabelled RNA products were measured by PhosphorImager (Fuji Bas-1500) and analysed using the Aida software.
Gel filtration through Superdex 200
PspF 1-275 WT and variants (at different concentrations) were incubated for 5 minutes at 4°C in buffer containing 20 mM Tris-HCl (pH 8.0), 50 mM NaCl and 15 mM MgCl 2 , ± 0.5 mM ATP or ADP where indicated. 50 µl samples were then injected onto a Superdex 200 column (10 × 300 mm, 24 ml, GE Healthcare) and equilibrated with the sample buffer ± nucleotide. Chromatography was performed at 4°C at a flow rate of 0.5 ml/min and columns were calibrated with globular proteins: thyroglobulin (669 kDa), apoferritin (443 kDa), b-amylase (200 kDa), bovine serum albumin (66 kDa) and carbonic anhydrase (29 kDa). All experiments were repeated at least twice and the elution profiles obtained were similar. Proteins were detected at 280 nm .
β-galacosidase assays
To perform in vivo, β-galacosidase assays, variant constructs were sub-cloned from pET28b to pBAD18C using XbaI/HindIII restriction enzyme. After transformation into cells containing a pspA-lacZ reporter construct inserted on the chromosome, cells were grown overnight at 37 o C in LB broth containing the appropriate antibiotic and then diluted 100-fold (initial OD 600 ≈0.025) into the same medium (5 ml). Following incubation to OD 600 ≈0.30, cultures were induced with arabinose for 1 h, further grown to mid-exponential phase (OD 600 ≈0.5-0.6) and then assayed for β-galactosidase activity as described by (Miller, 1972) . Enzyme activities (in Miller units) represent the means ± SD of the triplicate average values from at least six independent cultures. Oligomerization is one of the conserved properties of AAA+ proteins needed for the formation of the active catalytic site at the interface between subunits. We observed that the substitution of almost all the residues targeted in this study (except for L9 and E125) have a major effect on the oligomerization, favouring formation of a hexameric state similar to the one observed for the WT in the presence of nucleotide. This outcome is in complete agreement with studies suggesting that the PspF hexamer exists in a conformation non-functional for stable binding σ 54 in the absence of nucleotide, insured by the complex interaction network between the residues located at the level of the interface (Joly and Buck, 2010) . Substitution of the residues taking part in this network will "unlock" the conformation and the hexamer will adopt an "activate conformation". In the case of L9A and E125D, the oligomer formation is reduced compare to WT, but is still dependent on the protein concentration and/or on the presence of nucleotide.
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C. Figure S2 , related to Figure 3: ATPase activity of the mixed PspF between A. cis (N64, D107 and E108) and all variants used in this study, B. cis (N64, D107, E108 and Y126) and E43 variants. Histograms represent the k cat observed for the different variants mixed at equi-molar concentration. Experiment was performed three times independently and the maximal error observed was below 10%. C. preliminary experiment showing in vivo activity of the PspF variants. We used β-galatosidase activity assay of PspF 1-275 variants E125, R162, D164 and R168 overproduced in MG1655 ∆pspA∆pspF strain with chromosomal fusion of pspAp-lacZ.
We tested the effect of the substitution of few residues of PspF on its activity in vivo using a reporter strain harboring a pspAp-lacZ fusion on the chromosome and overproduced PspF variants. As shown in the preliminary results presented in the Figure S2SC , the activities of the variants tested are (when detected) very low and are consistent with the in vitro data. It is not possible to readily distinguish from the in vivo experiment whether the observed promoter activity reflects a reduction of the specific PspF activity or a reduction in the amount of active protein. As observed during protein purification, the substitution of a residue located at the interface between subunit often affects the solubility of the protein. Another limitation preventing us from conducting any in vivo "mixing" experiment, in the presence of two complementary substitutions, is the probable relative differences in the production of the variants in the same cell at the same time. Hence we did not perform a thorough systematic in vivo analysis with all the variants. Rather, in vitro methods based on using defined purified soluble proteins measured the effects of these substitutions upon activities. 
